TELL : +91 0 99 08 87 07 06

 Mcmed International ®: Largest Journal Publication in world

American Journal of Biological and Pharmaceutical Research

Volume 11, Issue 1, 2024
Mcmed International
American Journal of Biological and Pharmaceutical Research
Issn
2348 - 2176 (Print), 2348 - 2184 (Online)
Frequency
bi-annual
Email
editorajbpr@mcmed.us
Journal Home page
http://mcmed.us/journal/ajbpr
Recommend to
A Friend  | A librarian
Purchase
Purchase Issue
Abstract
Title
HUMAN SERUM ALBUMIN CARRIER FOR NEVIRAPINE NANOPARTICLES – A REVIEW
Author
Umasankar K* and Jayachandra Reddy P
Email
umasankar73@gmail.com
keyword
Anti-retroviral, HAS Carrier, HIV
Abstract
Human serum Albumin (HSA) is a bio-macromolecule and has a great attention in both fundamental and applied medication due to its biodegradability, non-toxicity nonimmunogenicity and regulatory function. For example, HSA could stabilize the ingredients in vaccines and modify the surface of medical devices. In addition the antioxidant property of HSA to construct possible innovated structure for therapeutic carriers. In fact HSA were used in frabicating albunex and ABI 007 for clinical purpose. Nanoparticles are prepared by following methods such as a) Amphiphilic macromolecules crosslinking b) Polymerization based methods c)Polymer precipitation methods d)Ionic gelation method. Considering the above factors, it is understood that delivery of nevirapine nanoparticles can greatly improve its solubility and bioavailability. HSA is a naturally occurring non immunogenic polymer and is considered advantageous for development of nevirapine nanoparticles. Desolvation method to prepare the nanoparticles. Therefore in the present study nevirapine nanoparticles was developed using HSA as a polymer by desolvation method and the nanoparticles was evaluated for physicochemical, in-vitro and in-vivo release characteristics.
Download Broucher
Back to Top >>>>